Michael M. Poe - Publications

Affiliations: 
Chemistry and Biochemistry University of Wisconsin-Milwaukee, Milwaukee, WI 

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Xu NZ, Ernst M, Treven M, Cerne R, Wakulchik M, Li X, Jones TM, Gleason SD, Morrow D, Schkeryantz JM, Rahman MT, Li G, Poe MM, Cook JM, Witkin JM. Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice. Psychopharmacology. PMID 29374303 DOI: 10.1007/s00213-018-4832-9  0.4
2017 Forkuo GS, Nieman AN, Yuan NY, Kodali R, Yu OB, Zahn NM, Jahan R, Li G, Stephen MR, Guthrie ML, Poe MM, Hartzler BD, Harris TW, Yocum GT, Emala CW, et al. Alleviation of Multiple Asthmatic Pathologic Features with Orally Available and Subtype Selective GABAA Receptor Modulators. Molecular Pharmaceutics. PMID 28440659 DOI: 10.1021/acs.molpharmaceut.7b00183  0.4
2017 Schwienteck KL, Li G, Poe MM, Cook JM, Banks ML, Stevens Negus S. Abuse-related effects of subtype-selective GABAA receptor positive allosteric modulators in an assay of intracranial self-stimulation in rats. Psychopharmacology. PMID 28365836 DOI: 10.1007/s00213-017-4615-8  0.4
2017 Fischer BD, Schlitt RJ, Hamade BZ, Rehman S, Ernst M, Poe MM, Li G, Kodali R, Arnold LA, Cook JM. Pharmacological and antihyperalgesic properties of the novel α2/3 preferring GABAA receptor ligand MP-III-024. Brain Research Bulletin. PMID 28267561 DOI: 10.1016/j.brainresbull.2017.03.001  0.4
2017 Lewter LA, Fisher JL, Siemian JN, Methuku KR, Poe MM, Cook JM, Li JX. Antinociceptive effects of a novel α2/α3-subtype selective GABAA receptor positive allosteric modulator. Acs Chemical Neuroscience. PMID 28150939 DOI: 10.1021/acschemneuro.6b00447  0.4
2016 Poe MM, Methuku KR, Li G, Verma AR, Teske KA, Stafford DC, Arnold LA, Cramer JW, Jones TM, Cerne R, Krambis MJ, Witkin JM, Jambrina E, Rehman S, Ernst M, et al. Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABAA) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy. Journal of Medicinal Chemistry. 59: 10800-10806. PMID 27933953 DOI: 10.1021/acs.jmedchem.6b01332  0.4
2016 Piantadosi SC, French BJ, Poe MM, Timić T, Marković BD, Pabba M, Seney ML, Oh H, Orser BA, Savić MM, Cook JM, Sibille E. Sex-Dependent Anti-Stress Effect of an α5 Subunit Containing GABAA Receptor Positive Allosteric Modulator. Frontiers in Pharmacology. 7: 446. PMID 27920723 DOI: 10.3389/fphar.2016.00446  0.4
2016 Jahan R, Stephen MR, Forkuo GS, Kodali R, Guthrie ML, Nieman AN, Yuan NY, Zahn NM, Poe MM, Li G, Yu OB, Yocum GT, Emala CW, Stafford DC, Cook JM, et al. Optimization of substituted imidazobenzodiazepines as novel asthma treatments. European Journal of Medicinal Chemistry. 126: 550-560. PMID 27915170 DOI: 10.1016/j.ejmech.2016.11.045  0.4
2016 Stamenić TT, Poe MM, Rehman S, Santrač A, Divović B, Scholze P, Ernst M, Cook JM, Savić MM. Ester to amide substitution improves selectivity, efficacy and kinetic behavior of a benzodiazepine positive modulator of GABAA receptors containing the α5 subunit. European Journal of Pharmacology. PMID 27639297 DOI: 10.1016/j.ejphar.2016.09.016  0.4
2016 Yuan NY, Poe MM, Witzigmann C, Cook JM, Stafford D, Arnold LA. Characterization of GABAA receptor ligands with automated patch-clamp using human neurons derived from pluripotent stem cells. Journal of Pharmacological and Toxicological Methods. PMID 27544543 DOI: 10.1016/j.vascn.2016.08.006  0.4
2016 Jonas O, Calligaris D, Methuku KR, Poe MM, Francois JP, Tranghese F, Changelian A, Sieghart W, Ernst M, Krummel DA, Cook JM, Pomeroy SL, Cima M, Agar NY, Langer R, et al. First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development. Journal of Biomedical Nanotechnology. 12: 1297-302. PMID 27319222 DOI: 10.1166/jbn.2016.2262  0.4
2016 Forkuo GS, Guthrie ML, Yuan NY, Nieman AN, Kodali R, Jahan R, Yocum GT, Treven M, Stephen MR, Poe MM, Li G, Yu OB, Hartzler BD, Zahn NM, Ernst M, et al. Development of GABAA Receptor Subtype-Selective Imidazobenzodiazepines as Novel Asthma treatments. Molecular Pharmaceutics. PMID 27120014 DOI: 10.1021/acs.molpharmaceut.6b00159  0.4
2015 Clayton T, Poe MM, Rallapalli S, Biawat P, Savić MM, Rowlett JK, Gallos G, Emala CW, Kaczorowski CC, Stafford DC, Arnold LA, Cook JM. A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model. International Journal of Medicinal Chemistry. 2015: 430248. PMID 26682068 DOI: 10.1155/2015/430248  0.4
2015 Botta P, Demmou L, Kasugai Y, Markovic M, Xu C, Fadok JP, Lu T, Poe MM, Xu L, Cook JM, Rudolph U, Sah P, Ferraguti F, Lüthi A. Corrigendum: Regulating anxiety with extrasynaptic inhibition. Nature Neuroscience. 18: 1862. PMID 26605888 DOI: 10.1038/nn1215-1862a  0.4
2015 Botta P, Demmou L, Kasugai Y, Markovic M, Xu C, Fadok JP, Lu T, Poe MM, Xu L, Cook JM, Rudolph U, Sah P, Ferraguti F, Lüthi A. Regulating anxiety with extrasynaptic inhibition. Nature Neuroscience. PMID 26322928 DOI: 10.1038/nn.4102  0.4
2015 Gallos G, Yocum GT, Siviski ME, Yim PD, Fu XW, Poe MM, Cook JM, Harrison N, Perez-Zoghbi J, Emala CW. Selective targeting of the α5-subunit of GABAA receptors relaxes airway smooth muscle and inhibits cellular calcium handling. American Journal of Physiology. Lung Cellular and Molecular Physiology. 308: L931-42. PMID 25659897 DOI: 10.1152/ajplung.00107.2014  0.4
2015 Richetto J, Labouesse MA, Poe MM, Cook JM, Grace AA, Riva MA, Meyer U. Behavioral effects of the benzodiazepine-positive allosteric modulator SH-053-2'F-S-CH₃ in an immune-mediated neurodevelopmental disruption model. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 18. PMID 25636893 DOI: 10.1093/ijnp/pyu055  0.4
2014 Obradović ALj, Joksimović S, Poe MM, Ramerstorfer J, Varagic Z, Namjoshi O, Batinić B, Radulović T, Marković B, Roth BL, Sieghart W, Cook JM, Savić MM. Sh-I-048A, an in vitro non-selective super-agonist at the benzodiazepine site of GABAA receptors: the approximated activation of receptor subtypes may explain behavioral effects. Brain Research. 1554: 36-48. PMID 24472579 DOI: 10.1016/j.brainres.2014.01.036  0.4
2014 Gill KM, Cook JM, Poe MM, Grace AA. Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. Schizophrenia Bulletin. 40: 341-50. PMID 24464874 DOI: 10.1093/schbul/sbt236  0.4
2013 Drexler B, Zinser S, Huang S, Poe MM, Rudolph U, Cook JM, Antkowiak B. Enhancing the function of alpha5-subunit-containing GABAA receptors promotes action potential firing of neocortical neurons during up-states. European Journal of Pharmacology. 703: 18-24. PMID 23380687 DOI: 10.1016/j.ejphar.2013.01.034  0.4
Show low-probability matches.